Background: Four medications are FDA approved for acute bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC)....
Objective: The aim of the current study was to evaluate the long-term safety and effectiveness of lurasidone in pediatric bipolar depression.
Method: Patients 10-17 years with bipolar I ...
Background: The elevated prevalence of metabolic syndrome (MetS) in patients with depression has been associated with increased mortality rates. The aim of this post-hoc analysis was to a...
Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated significant efficacy in treatment of binge-eating disorder (BED). We n...
Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated efficacy in the treatment of binge-eating disorder (BED). We now repor...
Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.
Objective: To evaluate the long-term safety and efficacy of lurasidone in children and adolescents with bipolar depression.
Methods: Patients (10-17 years) with bipolar depression who co...
Background: The aim of this post-hoc analysis was to evaluate the long-term efficacy of lurasidone in antipsychotic-naïve adolescents with schizophrenia.
Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia
Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...